Mod GRF 1-29 (CJC-1295 No Dac)

Description

Mod GRF 1-29 (CJC-1295 No Dac) Peptide Vials

Introduction

Mod GRF 1-29, also known as CJC-1295 No Dac, is a peptide designed exclusively for research purposes. It is developed to explore potential applications in growth hormone regulation and related processes, offering researchers a tool for scientific investigation.

Key Characteristics

CJC-1295 No Dac is notable for its potential to stimulate growth hormone release, CJC-1295 No Dac possesses characteristics conducive to extended biological activity.

Research Applications

This research peptide is formulated for scientific exploration into growth hormone-related processes. Researchers may utilize it to investigate its impact on various physiological aspects, contributing to a deeper understanding of its applications.

Research Benefits

CJC 1295 No DAC and Anti-Aging Tissue Repair

Studies may focus on the potential of CJC-1295 No Dac in anti-aging research, exploring its effects on tissue repair and regeneration processes.

CJC 1295 No DAC and Improving Cognitive Function

Researchers may explore the peptide’s impact on cognitive function, aiming to understand its potential role in enhancing cognitive processes.

CJC 1295 No DAC and Treatment of Growth Hormone Deficiency

The peptide’s potential in addressing growth hormone deficiency may be investigated, providing insights into its applications for hormonal imbalances.

Summary

Mod GRF 1-29 (CJC-1295 No Dac) is a research peptide designed for scientific investigations into growth hormone-related processes. Researchers are encouraged to explore its potential benefits, including anti-aging tissue repair, cognitive function improvement, and its role in the treatment of growth hormone deficiency.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Maria Alba, Danilo Fintini, Alessia Sagazio, Betty Lawrence, Jean-Paul Castaigne, Lawrence A. Frohman, and Roberto Salvatori. American Journal of Physiology-Endocrinology and Metabolism 2006 291:6, E1290-E1294. [Read More].
2. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Mark Timms,  Katherine Ganio,  Grace Forbes,  Simon Bailey,  Rohan Steel. [Read More].
3. Timms M, Ganio K, Forbes G, Bailey S, Steel R. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Anal. 2019 Jun;11(6):804-812. doi: 10.1002/dta.2554. Epub 2018 Dec 25. PMID: 30489688. [Read More].